Patent Assignment
Reel/Frame 058312/0195
Security Interest
Recorded: 2021-11-23
Pages: 26
Assignor
ADHERA THERAPEUTICS, INC.
Executed: 2020-06-26
Assignee
CAVALRY FUND I LP
61 KINDERKARMACK ROAD, WOODCLIFF LAKE, NEW JERSEY, 07677
Covered Properties
(43)
Methods and Formulations for Modulating Lyn Kinase Activity and Treating Related Disorders
PCT:
PCT/US2006/032788 ↗
Amphoteric Liposomes and Their Use
Salt of Perindopril and Pharmaceutical Compositions Containing It
Components for producing amphoteric liposomes
Application:
10/505,093 →
Publication:
US 2005/0164963
Double-stranded ribonucleic acid molecules having ribothymidine
Application:
11/219,625 →
Publication:
US 2006/0142230
Methods for Modulating Lyn Kinase Activity and Treating Related Disorders
Methods For Treating Inflammatory Conditions
Nucleic Acid Compounds for Inhibiting Vegf Gene Expression and Uses Thereof
Application:
12/039,650 →
Publication:
US 2008/0286866
Bacteria mediated gene silencing
Application:
12/157,969 →
Publication:
US 2008/0311081
Alpha Crystalline Form of the Arginine Salt of Perindopril, a Process for Its Preparation and Pharmceutical Compositions Containing It.
Compounds and Methods for Treating Disorders Related to Glucose Metabolism
Methods of Identifying Activators of Lyn Kinase
Application:
12/527,801 →
Publication:
US 2010/0152215
Nucleic Acid Compounds for Inhibiting Vegf Family Gene Expression and Uses Thereof
Application:
12/528,508 →
Publication:
US 2010/0047909
E. Coli Mediated Gene Silencing of Beta-Catenin
Application:
12/618,401 →
Publication:
US 2010/0189691
Bacteria Mediated Gene Silencing
Methods Of Activating IRS-1 And AKT
Application:
12/669,574 →
Publication:
US 2010/0197710
Methods for Modulating Lyn Kinase Activity and Treating Related Disorders
Compositions for Bacterial Mediated Gene Silencing and Methods of Using Same
Compositions for Intranasal Delivery of Human Insulin and Uses Thereof
Methods And Formulations For Modulating Lyn Kinase Activity And Treating Related Disorders
Prevention Of Pancreatic Beta Cell Degeneration
Application:
13/700,191 →
Publication:
US 2013/0158055
Methods and Formulations for Treating Cardiovascular Disease
Methods For Treating Inflammatory Conditions
Treatment of Type I and Type Ii Diabetes
Application:
14/364,792 →
Publication:
US 2015/0190396
Methods Of Treating Dyskinesia And Related Disorders
Amphoteric Liposomes
Bacteria Mediated Gene Silencing
Methods Of Treating Dyskinesia And Related Disorders
Methods And Formulations For Modulating Lyn Kinase Activity And Treating Related Disorders
Methods Of Treating Sleep Disorders
Methods For Treating Inflammatory Conditions
Application:
15/231,059 →
Publication:
US 2017/0173004
Methods and Formulations for Modulating Lyn Kinase Activity and Treating Related Disorders
Treatment Of Adipocytes
Fixed Dose Combination for Pain Relief Without Edema
Application:
16/173,924 →
Publication:
US 2019/0125727
Fixed Dose Combination for Pain Relief Without Edema
Application:
16/206,953 →
Publication:
US 2019/0091243
Methods Of Treating Dyskinesia And Related Disorders
Methods And Formulations For Modulating Lyn Kinase Activity And Treating Related Disorders
Prevention of Pancreatic Cell Degeneration
Treatment of Type I and Type Ii Diabetes
Application:
16/737,200 →
Publication:
US 2020/0215068
Treatment Of Liver Diseases
Application:
16/970,543 →
Publication:
US 2021/0106581
Treatment Of Adipocytes
Methods And Formulations For Modulating Lyn Kinase Activity And Treating Related Disorders
Treatment of Acute Respiratory Distress Syndrome (ARDS)
Application:
17/388,299 →
Publication:
US 2022/0031700
Related Assignments
(14)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Dec 8, 2009
From: FRUEHAUF, JOHANNES; VAZE, MORESHWAR BHANUDAS; LAROUX, FLOYD STEPHEN, JR.; SAUER, NOEL JOY
To: CEQUENT PHARMACEUTICALS, INC.
Reel/Frame 023618/0347 →
Assignment of Assignor's Interest
Dec 16, 2009
From: REAUME, ANDREW; SAPORITO, MICHAEL
To: MELIOR PHARMACEUTICALS I, INC.
Reel/Frame 023659/0669 →
Assignment of Assignor's Interest
Dec 16, 2009
From: MELIOR DISCOVERY, INC.
To: MELIOR PHARMACEUTICALS I, INC.
Reel/Frame 023659/0389 →
Security Agreement
Dec 29, 2009
From: MDRNA, INC.; MDRNA RESEARCH, INC.; NASTECH PHARMACEUTICAL COMPANY, INC.
To: EOS HOLDINGS LLC, AS AGENT
Reel/Frame 023708/0389 →
Change of Name
Jan 21, 2010
From: NASTECH PHARMACEUTICAL COMPANY INC.
To: MDRNA, INC.
Reel/Frame 023827/0675 →
Release of Security Interest
Feb 23, 2010
From: EOS HOLDINGS LLC, AS AGENT
To: MDRNA, INC.; MDRNA RESEARCH, INC.; NASTECH PHARMACEUTICAL COMPANY, INC.
Reel/Frame 023973/0286 →
Release of Security Interest
Apr 14, 2014
From: GENESIS CAPITAL MANAGEMENT, LLC, AS AGENT
To: MARINA BIOTECH, INC.; CEQUENT PHARMACEUTICALS, INC.; MDRNA RESEARCH, INC.
Reel/Frame 032685/0158 →
Change of Name
Mar 15, 2015
From: MDRNA, INC.
To: MARINA BIOTECH, INC.
Reel/Frame 035204/0245 →
Merger
Mar 15, 2015
From: CEQUENT PHARMACEUTICALS, INC.
To: MDRNA, INC.
Reel/Frame 035167/0931 →
Change of Name
Jun 16, 2020
From: MARINA BIOTECH, INC.
To: ADHERA THERAPEUTICS, INC.
Reel/Frame 052957/0901 →
Assignment of Assignor's Interest
Jun 16, 2020
From: ADHERA THERAPEUTICS, INC.
To: NOVOSOM VERWALTUNGS GMBH
Reel/Frame 052955/0256 →
Assignment of Assignor's Interest
Jun 16, 2020
From: NOVOSOM VERWALTUNGS GMBH
To: BIONTECH PROTEIN THERAPEUTICS GMBH
Reel/Frame 052958/0867 →
Change of Name
Jun 16, 2020
From: BIONTECH PROTEIN THERAPEUTICS GMBH
To: BIONTECH DELIVERY TECHNOLOGIES GMBH
Reel/Frame 052957/0904 →
Release of Security Interest
Jul 9, 2020
From: MONSANTO COMPANY
To: MARINA BIOTECH, INC.; CEQUENT PHARMACEUTICALS, INC.; MDRNA RESEARCH, INC.
Reel/Frame 053171/0508 →